Overview
Illexcor Therapeutics is a pre-clinical stage biopharmaceutical company focused on the discovery of oral drugs for sickle cell disease and other small molecule drug discovery pipeline programs. Our lead drug ILX002 is currently undergoing an IND program following a meeting with FDA and is advancing into a planned first-in-human clinical trial. Illexcor Therapeutics is also evaluating small molecule compounds for other hematologic, respiratory, and inflammatory disorders.